Diabetes Education News

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone improved outcomes compared with placebo regardless of baseline diabetes status, according to new data from the FINEARTS-HF trial.

Adults with type 2 diabetes at high risk for cardiovascular events were more likely to sustain an HbA1c of 6.5% or less at 2 years with tirzepatide if they lost more weight and had improved beta-cell function, according to new data.

Adults who eat greater amounts of meat may have increased risk for developing type 2 diabetes, according to data published in The Lancet Diabetes & Endocrinology.

Young children at high genetic risk for type 1 diabetes may be more likely to progress to the disease based on their dietary intake, according to a presenter at the European Association for the Study of Diabetes annual meeting.

Type 2 diabetes has emerged as a possible risk factor contributing to the development of dementia, but one class of agents used to treat the disease may provide greater protective effects, study results published in BMJ showed.

Once-weekly insulin efsitora alfa provided similar reductions in HbA1c as once-daily insulin degludec among insulin-naive adults with type 2 diabetes and adults with type 1 diabetes previously receiving a basal and bolus insulin analog.

The FDA has granted 510(k) clearance for an insulin patch pump for adults with type 1 or type 2 diabetes, Embecta Corp. announced.

With new guidance now available on monitoring people with early-stage type 1 diabetes, it is crucial for providers to encourage people at high risk to get tested, according to a presenter.

Pregnant women with diabetes can use automated insulin delivery systems with settings optimized to achieve tight glycemic targets, according to two speakers at the Association of Diabetes Care and Education Specialists annual meeting.

A novel once-weekly basal insulin conferred noninferior HbA1c reductions compared with daily insulins for insulin-naive adults with type 2 diabetes and those who switched from daily injections, according to topline results from two trials.